0000905148-24-000773.txt : 20240221 0000905148-24-000773.hdr.sgml : 20240221 20240221162010 ACCESSION NUMBER: 0000905148-24-000773 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240220 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lumira Capital Investment Management Inc. CENTRAL INDEX KEY: 0001702636 ORGANIZATION NAME: STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41854 FILM NUMBER: 24659802 BUSINESS ADDRESS: STREET 1: 141 ADELAIDE STREET WEST STREET 2: SUITE 770 CITY: TORONTO STATE: A6 ZIP: M5H 3L5 BUSINESS PHONE: 416-213-4223 MAIL ADDRESS: STREET 1: 141 ADELAIDE STREET WEST STREET 2: SUITE 770 CITY: TORONTO STATE: A6 ZIP: M5H 3L5 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: enGene Holdings Inc. CENTRAL INDEX KEY: 0001980845 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1031 BUSINESS ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 BUSINESS PHONE: (514) 332-4888 MAIL ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 4 1 form4.xml X0508 4 2024-02-20 true 0001980845 enGene Holdings Inc. ENGN 0001702636 Lumira Capital Investment Management Inc. 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5 ONTARIO, CANADA true false Common Shares 2024-02-20 4 A 0 644965 10 A 993651 I Held by Lumira Ventures IV, L.P. Common Shares 2024-02-20 4 A 0 155035 10 A 238851 I Held by Lumira Ventures IV (International), L.P. Common Shares 1341790 I Held by Lumira Ventures III, L.P. Common Shares 44647 I Held by Lumira Ventures III (International), L.P. Common Shares 1077386 I Held by Merck Lumira Biosciences Fund, L.P. Common Shares 152974 I Held by Merck Lumira Biosciences Fund (Quebec), L.P. This Form 4 is filed jointly by Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"), Lumira Capital Investment Management Inc. ("Lumira Mgmt"), Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc. and Lumira GP Holdings Co. (collectively, the "Reporting Person"). Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Mgmt. Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. Gerald Brunk, a director of the Issuer, is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt and reports his beneficial ownership of these securities on a separate Form 4. Each of Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any. Mr. Brunk serves on the Issuer's Board of Directors (the "Board") as a representative of the Reporting Person. By virtue of his representation on the Board, for purposes of Section 16 of the Exchange Act, the Reporting Person may be deemed to be a director of the Issuer by deputization of Mr. Brunk. /s/ Vasco Larcina, CFO of Lumira Capital Investment Management Inc. 2024-02-21